Patrick Neven, Sileny N. Han. "PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations." Nature Reviews Clinical Oncology (2025). https://doi.org/10.1038/s41571-025-01062-6